HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech companies that look promising.
One of the most intriguing biotech companies on the market is Endonovo Therapeutics, Inc. (ENDV). The company has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company's already rapid growth and that in turn could draw the attention of potential large investors. Do your due diligence on ENDV; it may be the next big winner in the biotech industry.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Histogenix Corporation (HSGX), Novavax, Inc. (NVAX), Kitov Pharma Ltd. (KTOV), and Celldex Therapeutics, Inc. (CLDX).
The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. The aforementioned Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $12.294M, Share Price: $0.0283), a commercial-stage developer of non-invasive wearable ElectroceuticalsTM Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non- invasive easy to use ORTHOHALOTM device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The company just released a shareholder letter. In it there is a list of the company's latest accomplishments. The list below is pretty impressive and is a big reason why the company is starting a major rally.
⦁ Signing two marketing agreements with well-established medical device sales organizations
⦁ Establishment and expansion of a rapidly growing sales department
⦁ The completion of the purchase price to the seller of the SofPulse Technology
⦁ The new Roma medical device is on schedule for release in Q1 of 2019
ENDV also announced an agreement with Azure Capital that will bring the company up to $10 Million for general corporate purposes, including working capital. This is a major development that could expedite the company's growth. Now is the time to start your research on ENDV.
Histogenix Corporation (HSGX) (Market Cap: $9.602M, Share Price: $0.1548)reported an update on their NeoCart regulatory pathway based on discussions with the FDA indicating that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.
Novavax, Inc. (NVAX) (Market Cap: $784.842M, Share Price: $2.05) in an effort to retain a strong, cohesive leadership team, announced in early December that the Company would be promoting Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology.
Kitov Pharma Ltd. (KTOV) (Market Cap: $20.054, Share Price: $1.33) just announced that it has entered into definitive agreements with institutional investors providing for the issuance of 3,428,572 American Depositary Shares at a purchase price of $1.75 per ADS in a registered direct offering.
Celldex Therapeutics, Inc. (CLDX) (Market Cap: $58.897M, Share Price: $0.3415)presented data from the Company's MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rdAnnual Meeting. MerTK is emerging as a promising target for cancer immunotherapy. Its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve monthagreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC